98 completed, 57 recruiting, 36 terminated, 35 active not recruiting. 106 Phase 2, 103 Phase 1, 47 Not applicable, 17 Phase 3, 3 Early Phase 1.
Follow Pancreatic Adenocarcinoma: new trials by email Literature Review of Pancreatic Adenocarcinoma trials Research Report on Pancreatic Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study Standard of Care - ePRO, Symptom Monitoring | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-02-21 | 2026-09-21 |
| Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency Lorigerlimab - Pancreatic Adenocarcinoma, Homologous Recombination Deficiency | Phase 2 | Not yet recruiting | University of Miami | 40 | 2027-01-01 | 2026-10-13 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) PCX-12 - Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | Haoming (Carl) Qiu | 24 | 2026-12-01 | 2026-02-05 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy Hydrocortisone, Pancreatic resection - Pancreatic Cancer, Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-01 | 2026-09-01 |
| Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy SMA-first pancreaticoduodenectomy using either right posterior or anterior approach. SMA identified and isolated with peri-adventitial dissection before any irreversible section., Conventional pancreaticoduodenectomy without prior isolation of the SMA; antero-posterior approach of the uncinate process after pancreatic section. - Pancreatic Adenocarcinoma, Pancreatic Head Cancer | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 150 | 2026-09-01 | 2026-04-23 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Atebimetinib, GnP, mGnP - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Immuneering Corporation | 510 | 2026-06-05 | 2026-10-16 |
| A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma CS08399 - Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 186 | 2026-06-01 | 2026-05-13 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer DaRT seeds insertion - Pancreatic Cancer, Unresectable Pancreatic Cancer | Not applicable | Recruiting | Alpha Tau Medical LTD. | 15 | 2026-05-06 | 2026-06-16 |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors ASP546C - Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 150 | 2026-05-04 | 2026-09-22 |
| A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors L19IL2, Ruxolitinib - Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Not yet recruiting | Philogen S.p.A. | 96 | 2026-05-01 | 2026-05-05 |
| FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers TEP-TDM au 68Ga-FAPI-46 - Cholangiocarcinoma, Pancreatic Adenocarcinoma | Phase 2 | Recruiting | University Hospital, Bordeaux | 120 | 2026-04-21 | 2026-04-30 |
| Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma Stereotactic body radiotherapy, Defactinib, Avutometinib - Pancreatic Adenocarcinoma, Cancer of the Pancreas | Phase 2 | Recruiting | Washington University School of Medicine | 36 | 2026-04-10 | 2026-04-15 |
| MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer Electronic Health Record Review, Smartphone Application-based Intervention, Survey Administration - Pancreatic Adenocarcinoma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 30 | 2026-03-10 | 2026-06-02 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 900 | 2026-03-09 | 2026-10-02 |
| To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. Pancreatectomy, Complete Cytoreduction, Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer | Not applicable | Recruiting | Unidade Local de Saúde São João, Oporto | 20 | 2026-03-01 | 2026-03-25 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
Showing 20 of 287. Sign in to see all of them.
Pancreatic Neoplasms (109) · Colorectal Neoplasms (26) · Carcinoma, Non-Small-Cell Lung (25) · Neoplasms (25) · Adenocarcinoma (19) · Neoplasm Metastasis (19) · Cholangiocarcinoma (15) · Ovarian Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (14) · Stomach Neoplasms (12) · Breast Neoplasms (11) · Carcinoma, Hepatocellular (11) · Melanoma (11) · Triple Negative Breast Neoplasms (10) · Carcinoma, Renal Cell (9)
Neoplasms (162) · Neoplasms by Site (160) · Digestive System Diseases (151) · Digestive System Neoplasms (147) · Endocrine Gland Neoplasms (132) · Endocrine System Diseases (132) · Pancreatic Diseases (115) · Neoplasms by Histologic Type (75) · Neoplasms, Glandular and Epithelial (70) · Carcinoma (61) · Gastrointestinal Diseases (44) · Gastrointestinal Neoplasms (40) · Adenocarcinoma (36) · Intestinal Diseases (35) · Intestinal Neoplasms (35)
Gemcitabine (70) · Albumin-Bound Paclitaxel (35) · 130-nm albumin-bound paclitaxel (27) · Fluorouracil (25) · Leucovorin (21) · Irinotecan (20) · Oxaliplatin (19) · Taxes (19) · Capecitabine (10) · pembrolizumab (10) · Cisplatin (9) · dehydroftorafur (9) · Radiosurgery (7) · Radiotherapy, Intensity-Modulated (7) · durvalumab (7)
M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (6) · Revolution Medicines, Inc. (5) · Alpha Tau Medical LTD. (4) · Fudan University (4) · Memorial Sloan Kettering Cancer Center (4) · Assistance Publique - Hôpitaux de Paris (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · OHSU Knight Cancer Institute (3) · Theriva Biologics SL (3) · University Hospital, Toulouse (3) · University of Chicago (3) · University of Nebraska (3) · AdventHealth (2) · Alliance for Clinical Trials in Oncology (2)
United States (163) · France (28) · Italy (23) · Spain (21) · China (20) · United Kingdom (17) · Canada (15) · Germany (13) · Belgium (12) · Japan (9) · South Korea (8) · Israel (7) · Netherlands (6) · Switzerland (6) · Australia (4)
Anwaar Saeed, MD (2) · Aslam Ejaz, MD (2) · Davendra Sohal (2) · Erkut Borazanci, MD (2) · Guopei Luo, MD (2) · Limor Appelbaum, MD (2) · Matthew H Katz (2) · Vincent J Picozzi, MD (2) · A. James Moser, MD (1) · A. Scott Paulson, MD (1) · Adrian Saftoiu, Professor (1) · Ajay Goel, PhD (1)
PMID 27840089, PMID 19855966, PMID 20189503, PMID 21437851, PMID 21963957, PMID 22576338, PMID 24327518, PMID 24829746, PMID 25512461, PMID 25795132, PMID 25931518, PMID 26154128, PMID 26527777, PMID 27280632, PMID 27424289, PMID 27543600, PMID 27701653, PMID 27744037, PMID 28053024, PMID 28143873, PMID 28258416, PMID 28267695, PMID 28356973, PMID 28527133, PMID 28672195, PMID 28750659, PMID 29325707, PMID 29383130, PMID 29574126, PMID 29667116, PMID 29756206, PMID 29843755, PMID 29846250, PMID 29852194, PMID 30080723, PMID 30120957, PMID 30216219, PMID 30225601, PMID 30240298, PMID 30326968, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31157963, PMID 31242873, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31843588, PMID 31882719
2023 (3), P30CA036727 (3), 2008 (2), 2016 (2), 2019 (2), 2025 (2), P30CA014599 (2), U10CA021661 (2), U10CA180868 (2), UM1CA186644 (2), 1UG3CA283652-01 (1), 2009 (1), 2014 (1), 2015 (1), 2017 (1)